期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2015年下半年美国FDA批准的新分子实体与评价:呼吸、血液和代谢系统疾病治疗用药以及解毒剂 被引量：2

Updates of New Molecular Entities Approved by the FDA in the Second-Half of 2015:Respiratory,Hematology,Metabolic Diseases and Antidotes
下载PDF
导出
摘要 2015年下半年,FDA批准了31个新分子实体和新生物制品。本文将介绍和评价呼吸、血液和代谢系统疾病治疗用药以及解毒剂。 The US FDA approved 31 new molecular entities and new therapeutic biological products in the second-half of 2015. This article provides an update and evaluation of the new drugs approved for the treatment of respiratory, hematology and metabolic diseases,and antidotes.
作者 孙树森 赵志刚
机构地区 美国西新英格兰大学药学院 首都医科大学附属北京天坛医院药学部
出处 《药品评价》 CAS 2016年第4期12-19,共8页 Drug Evaluation
关键词 FDA 2015年 新分子实体 呼吸系统疾病 血液系统疾病 代谢系统疾病 解毒剂 FDA 2015 New Molecular Entity Respiratory Hematology Metabolic Disease Antidotes
分类号 R95 [医药卫生—药学]
  • 相关文献

参考文献17

二级参考文献70

  • 1陈新谦,金有豫,汤光,主编.新编药物学第[M].第17版.第50章:抗凝血药.北京:人民卫生出版社.
  • 2European Heart Rhythm Association, Camm AJ, Kirchhof P, et al. Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC).Guidelines for the management of atrial fibrillation[J]. Eur Heart J, 2010, 31(19): 2369-2429.
  • 3Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10):883-891.
  • 4Granger CB, Alexander JH, McMurray J J, et al. Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med, 2011,365(11):981-992.
  • 5Larsen TB, Lip GY. Warfarin or noveloral anticoagulants for atrial fibrillation?[J]. Lancet, 2014, 383(9921): 931-933.
  • 6January CT, Wann ST, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. Circulation, 2014, 130(23): 2071-2104.
  • 7Warfarin sodium tablet[OL]. DailyMed. http://daitymed.nlm.nih. gov/dailymed/druglnfo.cfm. 2014-8-14/2014-12-20.
  • 8Dabigatran etexilate mesylate capsule[OL]. DailyMed. http:// dailymed.nlm.nih.gov/dailymed/druglnfo.cfm. 2014-11-14/2014- 12-20.
  • 9Rivaroxaban table[OL]. DailyMed. http://dailymed.nlm.nih.gov/ dailymed/druglnfo.cfm. 2014-11 - 14/2014-12-20.
  • 10Apixaban tablet[OL]. DailyMed. http://dailymed.nlm.nih.gov/ dailymed/druglnfo.efm.2014-8-14/2014-12-20.

共引文献26

同被引文献18

  • 1Lokhorst HM, Plesner T, Laubach JP, et al. Taergeting CD38 withdaratumumab monotherapy in multiple myeloma[J]. N Eng J Med, 2015,373(13): 1207-1219.
  • 2Lonial S, Weiss B, Usmani S, et al. Phase 2 study of daratumumabmonotherapy in patients with > 3 lines of prior therapy or double refractorymultiple myeloma: 5476414MMY2002(SIRIUS)[abstract no. S430].Haemotologica. 2015, 100(Suppl1): 153.
  • 3Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment[J].Mayo Clin Proc, 2016, 91(1): 101-119.
  • 4Shirley M. Ixazomib: first global approval[J]. Drugs, 2016, 76(3): 405-411.
  • 5Markham A. Elotuzumab: first global approval[J]. Drugs, 2016, 76(3): 397-403.
  • 6Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib andcobimetinib in BRAF-mutated melonoma[J]. N Engl J Med, 2014, 371(20):1867-1876.
  • 7Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety oftrabectedin or dacarbazine for metastatic liposarcoma or leimyosarcomaafter failure of conventional chemotherapy: results of a phase 3 randomizedmulticenter clinical trial[J]. J ClinOncol, 2015 Sep 14. pii: JCO. 2015. 62.4734. [Epub ahead of print].
  • 8Nakamura T, Matsumine A, Sudo A. The value of trabectedin in thetreatment of soft tissue sarcoma[J]. TherClin Risk Manag, 2016, 12: 73-79.
  • 9Greig SL. Osimertinib: first global approval[J]. Drugs, 2016, 76: 263-273.
  • 10Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabineand cisplatin versus gemcitabine and cisplatin alone as first-line therapy inpatients with stage IV squamous non-small-cell lung cancer (SQUIRE): anopen-label, randomized, controlled phase 3 trial[J]. Lancet Oncol, 2015,16: 763-774.

二级引证文献4

药品评价
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部